Views & Analysis | Perspectives on pharma industry issues

Skip to main content

Tuesday 10 November 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Patients

Claire Gillis, CEO - VML Health

Healthcare wants patients at the centre. So, why are they st...

Claire Gillis reflects on a surprising controversy at ESMO 2026, and the uncomfortable questions it raises for healthcare.

Digital

Synthetic data idea, motherboard and lights

The growing use of synthetic data in modern pharma

The issue isn't whether synthetic data is useful. It is what question we are asking it to answer.

R&D

Aedes aegypti mosquito

Europe’s growing vector-borne disease threat: Are we keeping...

In Europe, diseases once largely associated with tropical or subtropical regions are becoming a more immediate concern.

R&D

Digital illustration of the kidneys

Kidney care raises its ambitions at ASN Kidney Week 2026

Following ASN Kidney Week 2026, pharmaphorum spoke with Hansa Biopharma's Maria Törnsén and Tes Pharma's Andrea Pellacani about the conference.

Oncology

Digital concept of a lung cancer vaccine

Lung cancer vaccine renews synthetic DNA discussions

pharmaphorum spoke with Dr Amy Walker, CEO of 4basebio, about personalised cancer vaccines and synthetic DNA.

Articles

FDA ‘breakthrough’ status – a new tool for building oncology brands?

FDA ‘breakthrough’ status – a new tool for building oncology...

Kelly Price looks at a new regulatory status and how Oncology Brands are using it to their advantage.

Articles

The future of cancer care

The future of cancer care

In our oncology themed month, Professor Karol Sikora of Cancer Partners UK offers a glimpse into the cancer treatment environment of tomorrow and why he thinks we will see huge advances in canc

Articles

Patient perspectives: Les Halpin

Patient perspectives: Les Halpin

Motor Neurone Disease (MND) patient Les Halpin speaks with pharmaphorum's Rebecca Aris on how we need to speed up the drug approval processes for diseases such as MND.

Load more results

Sales & Marketing

Sales & Marketing

Solution Spotlight: BrandPRO Biopharma

Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Digital

Digital

Synthetic data idea, motherboard and lights

The growing use of synthetic data in modern pharma

The issue isn't whether synthetic data is useful. It is what question we are asking it to answer.

Digital

AI graphic concept

AI is exposing a new digital maturity divide in pharma busin...

As AI adoption increases, it is exposing just how prepared organisations really are to operate in a digitally connected environment.

Market Access

Market Access

MDM concept of patient data

Sponsored

The pre-commercial case for connecting data before acquiring...

For EBPs, launch requires a data strategy that starts with agreement on the KPIs, and those depend on the therapeutic areas.

Market Access

Two pills in the middle of multiple £1 coins

UK’s next pricing and access scheme to last for 7 years

Operational review meeting minutes released by the DHSC reveal industry and government are planning to move to a 7-year agreement.

Editor's Picks

Boehringer forges $7bn alliance with China's SBP Group News

Lilly partners with Hims & Hers on obesity drug sales

UK women's health firm Theramex sold for around £2.2bn

What do midterms mean for Trump's pharma and health agenda?

NICE backs Keytruda/Padcev combo for bladder cancer

Newsletters and Deep Dive
digital magazine

Get Newsletters

Get in-depth news, opinions, and features on pharma and healthcare sent straight to your inbox

Oncology

Oncology

Digital concept of a lung cancer vaccine

Lung cancer vaccine renews synthetic DNA discussions

pharmaphorum spoke with Dr Amy Walker, CEO of 4basebio, about personalised cancer vaccines and synthetic DNA.

Oncology

Woman with breast cancer and female HCP

How precision medicine treats an overlooked clinical variabl...

In oncology, time is not simply a measure of care; it is a clinical variable – and increasingly a therapeutic challenge.

Oncology

On the benefits of earlier oncological intervention, with Johnson & Johnson

On the benefits of earlier oncological intervention, with Jo...

As ESMO 2026 came to a close, pharmaphorum web editor Nicole Raleigh spoke with Johnson & Johnson Innovative Medicine’s Carolyn Sousa and Henar Hevia

Patients

Patients

Claire Gillis, CEO - VML Health

Healthcare wants patients at the centre. So, why are they st...

Claire Gillis reflects on a surprising controversy at ESMO 2026, and the uncomfortable questions it raises for healthcare.

Deep Dive

Why are so few sickle cell disease patients using a widely available treatment?

Why are so few sickle cell disease patients using a widely a...

Patients

TMS being given to female patient by female HCP.

TMS works. Why do fewer than 1% of eligible patients get it?

A growing body of clinical evidence suggests that TMS can produce response rates of roughly 50-60% or higher.

R&D

R&D

Aedes aegypti mosquito

Europe’s growing vector-borne disease threat: Are we keeping...

In Europe, diseases once largely associated with tropical or subtropical regions are becoming a more immediate concern.

R&D

Digital illustration of the kidneys

Kidney care raises its ambitions at ASN Kidney Week 2026

Following ASN Kidney Week 2026, pharmaphorum spoke with Hansa Biopharma's Maria Törnsén and Tes Pharma's Andrea Pellacani about the conference.

R&D

Challenging the clinical trial plan

Why the best CROs challenge the trial plan and keep challeng...

Too often, oncology trials fail for reasons that could have been anticipated and addressed.

Editor's Picks

Boehringer forges $7bn alliance with China's SBP Group News

Lilly partners with Hims & Hers on obesity drug sales

UK women's health firm Theramex sold for around £2.2bn

What do midterms mean for Trump's pharma and health agenda?

NICE backs Keytruda/Padcev combo for bladder cancer

News

globe with lights

Amazon puts $100m into global health drive

Amazon Web Services has committed $100m in AI and cloud technology capacity to support the building of health services for "underserved communities."

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company